Glaukos stock soars to all-time high, reaches $161.17

Published 01/21/2025, 12:52 PM
GKOS
-

Glaukos Corporation (NYSE:GKOS), a leader in the ophthalmic medical technology industry with a market capitalization of $8.85 billion, has achieved a remarkable milestone as its stock price soared to an all-time high of $161.17. According to InvestingPro analysis, the company currently trades above its Fair Value, with analyst price targets ranging from $120 to $185. This peak represents a significant triumph for the company, reflecting a robust performance and growing investor confidence. Over the past year, Glaukos has seen an impressive 71.3% increase in its stock value, backed by strong revenue growth of 18.7% and a healthy current ratio of 5.54, underscoring the company's strong market presence and its innovative solutions in the fight against glaucoma and corneal disorders. This surge to record levels marks a period of exceptional growth for Glaukos, as it continues to expand its reach and impact within the medical technology sector. Discover 12 additional key insights about GKOS with an InvestingPro subscription, including detailed financial health metrics and growth projections.

In other recent news, Glaukos Corporation disclosed sustained efficacy in the latest iDose TR clinical trials, with about 70% of subjects maintaining controlled intraocular pressure levels. The iDose TR also showed continued tolerability over a 36-month period. Furthermore, Glaukos has started a Phase 2b/3 clinical program for iDose TREX, an enhancement of the iDose technology.

Stifel analysts have raised their price target on Glaukos shares to $175, predicting fourth-quarter 2024 iDose sales to reach at least the mid-teen millions range. Meanwhile, Citi upgraded Glaukos from Neutral to Buy, anticipating a positive inflection in sales of its iDose product in 2025. Mizuho (NYSE:MFG) Securities retained a Neutral rating on Glaukos but increased the price target, foreseeing a significant year ahead for the company.

Additionally, Glaukos has submitted a New Drug Application to the U.S. Food and Drug Administration for Epioxa, a novel treatment for keratoconus. If approved, Epioxa would be the first FDA-sanctioned, non-invasive corneal cross-linking therapy. These are recent developments in Glaukos Corporation's journey.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.